U.S. District Court Judge Rudolph Contreras will hear arguments Dec. 21 in AHA's lawsuit to prevent the Centers for Medicare & Medicaid Services from reducing Medicare payments for hospital outpatient drugs under the 340B drug savings program by nearly 30%. AHA is joined in the lawsuit by the Association of American Medical Colleges and America's Essential Hospitals, as well as Eastern Maine Healthcare Systems in Brewer, ME, Henry Ford Health System in Detroit and Adventist Health System's Park Ridge Health in Hendersonville, NC. In the lawsuit, the groups argue that the administration's attempt to undermine 340B savings in the outpatient prospective payment system final rule for calendar year 2018 is unlawful and exceeds the Secretary of Health and Human Services' authority under Medicare law and the Public Health Services Act. HHS has until Dec. 1 to file its arguments in favor of dismissing the case. There will be other briefs with the final HHS brief due on Dec. 15. The cuts are scheduled to take effect Jan. 1, unless the district court judge enjoins the rule.

Related News Articles

Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law…
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models. “The 340B…
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at…